港股異動 | 百濟神州(6160.HK)漲6.6% 與安進共同開發的KRAS抑制劑sotorasib(AMG510)獲得新進展
格隆匯5月31日丨百濟神州(6160.HK)漲6.6%,報219.8港元,股價創逾3個月新高,總市值2623億港元。2021年5月29日,美國FDA宣佈加速批准安進公司開發的Lumakras(sotorasib,AMG510)上市,用於治療腫瘤攜帶KRAS G12C突變的非小細胞肺癌(NSCLC)患者。2019年11月,百濟神州(與安進達成全球腫瘤戰略合作,共同開發包括AMG 510在內的二十餘款療法。2021年1月12日,中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)網站公示,安進(Amgen)/百濟神州共同申報的KRASG12C抑制劑AMG 510(sotorasib)被納入擬突破性治療品種,擬定適應症為攜帶KRAS p.G12C突變的局部晚期或轉移性非小細胞肺癌(NSCLC)患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.